On Nov. 4, 2025, Colossal Biosciences, the world’s de-extinction company, today announced its acquisition of Viagen Pets and Equine, the global leader and expert in animal cloning. Viagen provides genetic preservation and cloning services for pets, equine, and some of the world’s most endangered species.

The Texas-based company will continue to operate under its current leadership as a wholly owned subsidiary of Colossal while expanding its endangered species cloning platform to additional threatened species and countries worldwide.

This marks Colossal’s first acquisition, following the successful gestation of two announced companies — Breaking and Form Bio —since the company’s launch in 2021.

Founded in Austin, Texas in 2002, Viagen has grown from a livestock and genetic preservation company into the global leader in animal reproduction and preservation services for pets, equine, livestock, and endangered species. Over the years, the company expanded through key acquisitions and partnerships, gaining exclusive licensing and access to the breakthrough technologies developed by the Roslin Institute of Edinburgh, best known for cloning Dolly the sheep.

In 2022, Viagen expanded beyond cloning into advanced reproductive technologies for horses. The company introduced Intracytoplasmic Sperm Injection (ICSI) services to the equine market — a specialized technique in which a single sperm is injected directly into an egg, empowering breeders with the ability to select the sex of foals. Leveraging Viagen’s leadership in the work of Somatic Cell Nuclear Transfer (SCNT), and decades of experience in the U.S. horse industry, Viagen seamlessly entered the ICSI space with unmatched expertise and innovation. Today, through cutting-edge technology, personalized care, and an exclusive license for Sexed Semen Technology from ST Genetics in the U.S. and Canada, Viagen continues to lead the field of advanced equine breeding science.